Navigation Links
New Anti-Rejection Medication 6-Month Results for Heart Transplant,Recipients to Be Released at International Heart and Lung,Transplant Meeting

ADDISON, Texas, April 19, 2007 /PRNewswire/ -- New clinical trial results for heart transplant patients will be released at the upcoming International Society for Heart and Lung Transplantation (ISHLT) 27th Annual Meeting and Scientific Sessions at the Hilton San Francisco, April 25-28, 2007. Results show promise for efficacy and safety of immunosuppression therapy and lower incidences of acute organ rejection in heart transplants.

    Research to be presented includes:

    --  Six Month Data on Cyclosporine Reduction and Impact on Renal Function

        with Everolimus In De Novo Heart Transplant Recipients will be

        presented Wednesday, April 25 during a luncheon symposium at 12:30pm

        PDT.

    --  6 Month Data from a 12 Month Study of Everolimus with Reduced

        Cyclosporine Exposure vs. MMF and Conventional Cyclosporine in De Novo

        Heart Transplant Recipients will be presented during the same luncheon

        symposium on April 25.

The leading cause of death during the first year following heart transplant is acute rejection of the transplanted organ. The patient's immune system attacks the heart as if it were a foreign object until it no longer functions properly. The one-year survival rate after transplantation is approximately 80 percent; this number drops to nearly 50 percent after 10 years.

About ISHLT

The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit organization dedicated to the advancement of the science and treatment of end-stage heart and lung diseases. Created in 1981, the Society now includes more than 2,200 members from 45-plus countries, representing a variety of disciplines involved in the management and treatment of end-stage heart and lung disease.

ISHLT manages two vital databases. The International Heart and Lung Registry is a one-of-a-kind registry that has been collecting data
'"/>




Page: 1 2

Related medicine technology :

1. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
2. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
3. New Data Focuses on Abuse of Stimulant Medication
4. Separate Sets of Research Show Treatment Improved Quality of Life in as Early as Three Weeks; Patient Adherence to Medication is Multifactorial
5. FDA Proposes New Warnings About Suicidal Thinking, Behavior in Young Adults Who Take Antidepressant Medications
6. Survey: Migraine Patients Taking Potentially Addictive Barbiturate or Opioid Medications Not Approved by FDA as Migraine Treatments
7. Drug for Treatment of Heart Failure Does Not Improve Survival, Compared to More Widely-used Medication
8. Study Sheds Light on Medication Treatment Options for Bipolar Disorder
9. Stanford Study Finds No Conclusive Benefit From Treating Kleptomania With Medication
10. Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase I/IIa 6-Month Results at 75th Annual Meeting of the American Association of Neurological Surgeons
11. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
Post Your Comments:
(Date:9/5/2008)...rom a Simple Blood Draw Have,the Potential to Serv...e of Indications,Usin... Currently Developing a Blood-Based ...JERSEY CITY, New Jersey, September 5,/PRNewswire-F... a leader in,the development of microRNA-based dia...
(Date:9/4/2008)...treatment of Acute Myeloid ...swire/ -- Celator Pharmaceuticals today,announced ... granted orphan,drug designation to CPX-351 (Cytar...atment of Acute Myeloid Leukemia (AML)., Celator ...hase 2,studies with CPX-351. The first Phase 2 stu...
(Date:9/4/2008)...R testing for the diagnostic ...ewswire/ -- The U.S. Food & Drug,Administration (F...Test,the first assay for quantitating Hepatitis B...e,s real-time PCR technology to quantify the amoun...octors may use viral load,testing results to estab...
(Date:9/4/2008)...ogists States UFE Meets Level,A Evidence for Clini...nal,Radiology Treatment Is Safe, Effective Option ...pt. 4 /PRNewswire-USNewswire/ -- The Society of,In... nearly 4,500 doctors,scientists and allied healt... through minimally invasive treatment intervention...
Breaking Medicine Technology:Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 2Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 3Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 4Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351 2FDA Approves First Hepatitis B Viral Load Test 2FDA Approves First Hepatitis B Viral Load Test 3Society of Interventional Radiology Applauds Report's Uterine Fibroid Embolization Recommendations 2Society of Interventional Radiology Applauds Report's Uterine Fibroid Embolization Recommendations 3Beavers can help ease drought 2279 1Beavers can help ease drought 2279 2Music Therapy Improves Stroke Outcomes 12359 1Music Therapy Improves Stroke Outcomes 12359 2Grant to study if early BPA exposure leads to late prostate cancer 12355 1Grant to study if early BPA exposure leads to late prostate cancer 12355 2Standard test for blood sugar control not accurate in diabetic dialysis patients 12354 1Standard test for blood sugar control not accurate in diabetic dialysis patients 12354 2
...E)--Mar 12, 2007 - Ceragenix Pharmaceuticals,Inc.... on,infectious disease and dermatology, today anno...pound demonstrated virtually no biofilm,formation ...heters treated with Ceragenins,were soaked daily i...eated catheter. At day 21, the catheters were chal...
... March 12, 2007: Progen Industries Limited,(ASX: P...PI-88,Phase II liver cancer data has been accepted...an Association for the Study of the Liver,(EASL). ... liver,cancer trial at the American Association fo...In expectation of having final data fully analysed...
Other Medicine Technology:Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 3PI-88 Data to be Presented at Key International Conferences 2PI-88 Data to be Presented at Key International Conferences 3
(Date:9/4/2008)...ate Medicare Advantage (MA) plans will be paid an ...pared to what the same enrollee would have cost in... according to a new report from The Commonwealth F...andated by the Medicare Improvements for Patients ...ke effect beginning in 2010 had been fully in pla...
(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...d pancreatic tumors , , THURSDAY, Sept. ...iscoveries involving genetic mutations of two dead...ncreatic cancer -- may lead to new treatments and ...represent the most complete genetic analysis to da...c map of these deadly cancers," Kenneth Kinzler, a...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
Breaking Medicine News(10 mins):Health News:Extra payments to Medicare Advantage plans to total $8.5 billion in 2008 2Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Genetic Mutations Linked to Deadly Cancers 2Health News:Genetic Mutations Linked to Deadly Cancers 3Health News:Genetic Mutations Linked to Deadly Cancers 4Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3
...an inquiry into four deaths allegedly due to power... circumstances leading to the deaths that occurred...ospital superintendent S.C. Tiwari told IANS. Ear...d denied the deaths were due to power cut, stating...
...lions of pounds that have gone into the NHS have b...ivitas here has been “little or no evidence of imp... worst in the developed world”. In addition it sa...creased in proportion to the vast sums ploughed in...
...Lusaka, Zambia, have explained that the programme ...rst two years.// The leaders made their report on...IDS Conference in Toronto. They explained that the... thought that it is simply not possible to provide...
...ing a pilot project in sterilisation of street dog...t their animal birth control (ABC) initiative acro...ions across Tamil Nadu and neighbouring states hav...t was successfully tried by the Chennai Corporatio...
Other Medicine News:Health News:The Aids Programme In Zambia Reported As A Success 2
Cruciate Retaining, Posterior Stabilized and Constrained Components.
...bilized knee has an advanced design which provides...surfacing and inset patellas. Precision machined c...fit with tibial articular surface and patella to r...rovide easy intraoperative change of sizes. Increa...
StelKast's Proven knee system is a long term, quality solution based on a clinically proven design. Available in both posterior stabilized and anatomically correct cruciate retaining configurations.
The Foundation Knee CR System was designed to replicate normal knee kinematics. The patello- femoral joint has a recessed, deepened and extended patella groove to minimize advancement of the patella,
Medicine Products: